ISPOR PUBLISHES NEW GLOBAL HEALTH CARE SYSTEMS ROAD MAP FOR DENMARK PHARMACEUTICALS

Published Jan 5, 2016
Princeton, NJ—January 5, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today that it has published a new Global Health Care Systems Road Map—Denmark Pharmaceuticals ISPOR Global Health Care Systems Road Maps provide an overview of country-specific, health care delivery systems. The Road Maps focus on reimbursement and pricing approval processes by country in one of three segments—pharmaceutical, medical devices, or diagnostics. ISPOR Global Health Care Systems Road Maps can benefit a variety of stakeholders—such as health care decision makers, payers, researchers, industry, clinicians, academicians, and students—who are interested in how a given country reimburses and approves pricing for health care technologies. ISPOR Global Health Care Systems Road Maps are validated by country-specific health care experts and are updated over time to reflect changes in the country’s health care delivery system. Denmark flag map According to the newly published ISPOR Global Health Care Systems Road Map—Denmark Pharmaceuticals, all Danish citizens are covered by national health insurance. The Danish Medicines Agency decides the reimbursement status for pharmaceutical products and is responsible for legislation concerning pharmaceuticals, medical devices, and clinical trials. Marketing authorization in Denmark is regulated according to European Union (EU) regulation by the European Medicines Agency and does not differ in Denmark from that of other European countries. The total public health care expenditure in Denmark for 2014 were 102,569 billion Danish Krone (DKK) and pharmaceutical spending constituted 12.4% of regional health care expenses. The ISPOR Global Health Care Systems Road Map—Denmark Pharmaceuticals may be found here. Other ISPOR Global Health Care Systems Road Maps published in 2015 include: -          USA – Pharmaceuticals -          Australia – Pharmaceuticals -          Australia – Medical Devices and Diagnostics   Additional information on all of the ISPOR Tools for Health Care Decision Makers may be found here.

###

 

Related Stories

ISPOR Announces 2025-2026 Board of Directors

May 20, 2025

ISPOR announced the results of its recent elections and its 2025-2026 Board of Directors. The 2025-2026 board will assume office on July 1.

Value in Health Journal Spotlights "Whole Health" in Special Series

May 19, 2025

Value in Health, the official journal of ISPOR, announced the publication of a series of articles exploring the concept of "whole health"—a holistic approach to healthcare that extends beyond the traditional biomedical model to incorporate physical, mental, social, environmental, and spiritual dimensions of wellbeing.

Rethinking Medication Adherence: A Stakeholder Blueprint

May 12, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a report from its Medication Adherence and Persistence Special Interest Group that provides valuable insights into the perspectives of key stakeholders on interventions to improve medication adherence. The report, “Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions: An ISPOR Report,” was published in the May 2025 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×